NeuroSense Therapeutics Ltd. (NRSN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

NeuroSense Therapeutics Ltd. (NRSN) closed at USD 3.06 on 2026-10-14, a change of -86.1 % over the past year, with a market capitalization of USD 6.01M.

NeuroSense Therapeutics Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

NeuroSense Therapeutics Ltd. key figures

Previous close

USD 3.06 (2026-10-14)

1-year change

-86.1 %

Market cap

USD 6.01M

Enterprise value

USD 5.61M

P/E ratio (trailing)

-0.07

P/E ratio (forward)

-0.68

EPS (trailing)

-42.78

EPS (forward)

-4.68

PEG ratio

n/a

Price to book

-3.31

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.88

Employees

17

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for NeuroSense Therapeutics Ltd. and compare it with other stocks.